LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Human natural regulatory CD4(+) T cells comprise 5-10% of peripheral CD4(+)T cells. They constitutively express the IL-2Ralpha-chain (CD25) and the nuclear transcription Foxp3. These cells are heterogeneous and contain discrete subsets with distinct phenotypes and functions. Studies in mice report that LAG-3 has a complex role in T cell homeostasis and is expressed in CD4(+)CD25(+) T regulatory cells. In this study, we explored the expression of LAG-3 in human CD4(+) T cells and found that LAG-3 identifies a discrete subset of CD4(+)CD25(high)Foxp3(+) T cells. This CD4(+)CD25(high)Foxp3(+)LAG-3(+) population is preferentially expanded in the PBMCs of patients with cancer, in lymphocytes of tumor-invaded lymph nodes and in lymphocytes infiltrating visceral metastasis. Ex vivo analysis showed that CD4(+)CD25(high)Foxp3(+)LAG-3(+) T cells are functionally active cells that release the immunosuppressive cytokines IL-10 and TGF-beta1, but not IL-2. An in vitro suppression assay using CD4(+)CD25(high)LAG-3(+) T cells sorted from in vitro expanded CD4(+)CD25(high) regulatory T cells showed that this subset of cells is endowed with potent suppressor activity that requires cell-to-cell contact. Our data show that LAG-3 defines an active CD4(+)CD25(high)Foxp3(+) regulatory T cell subset whose frequency is enhanced in the PBMCs of patients with cancer and is expanded at tumor sites.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, LAG3 can positively induce Treg cell activation and stimulate its immunosuppressive function [325, 326].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [326]
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Moreover, although data remain controversial and depend on the type of tumor studied (21), a higher accumulation of Treg cells is often associated with advanced disease stages and is inversely correlated with favorable prognosis and overall survival (22, 23).”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Baecher-Allan, C., Brown, J. A., Freeman, G. J., & Hafler, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1245 · Cited by 1,859
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“This same set of markers, together with a low expression level of CD127 (6, 7), also identifies human natural Treg cells.”
BackgroundICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255 · cited 1×
“Natural Treg cells, upon TCR engagement (15, 16), exert their immunosuppressive functions in a contact-dependent fashion.”
BackgroundInterleukin‐10‐secreting type 1 regulatory T cells in rodents and humans
Grazia Roncarolo, M., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00420.x · Cited by 1,173 · cited 1×
“Two subsets of induced Treg cells have been described and are shown to also exist in humans: Tr1 cells, which secrete high levels of IL-10 and arise from CD4 T cells upon encountering Ags in a tolerogenic environment (1), and Th3 cells, which are induced by oral Ag administration and secrete high levels of TGF-b1 (2).”
Background
Cited by
Items 201–300 of 350
CD4+ T cell dysfunction in cancer
Venkatesh, H., & Fong, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241417 · Cited by 23
Electronic Sorting of Immune Cell Subpopulations Based on Highly Plastic Genes
Wang, P., Han, W., & Ma, D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502552 · Cited by 21
“For example, Treg subpopulations, such as CXCR3 Tregs (50), HLA-DRA Tregs (51), TIM3 Tregs (52), CCR6 Tregs (53), LAG3 Tregs (54), and CD8A Tregs (55), were reported.”
Shirai, T., Konnai, S., Ikebuchi, R., Okagawa, T., Suzuki, S., Sunden, Y., Onuma, M., Murata, S., & Ohashi, K. (2011) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2011.08.018 · Cited by 23
Stier, M. T., Sewell, A. E., Mwizerwa, E. L., Sim, C. Y., Tanner, S., Nichols, C. M., Durai, H. H., Jennings, E. Q., Lindau, P., Wilfong, E. M., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02390-6 · Cited by 23
“T reg cells also exhibited functional and phenotypic differences in CI-NS and CI-Sep compared with NHCs. CI-NS and CI-Sep had a higher frequency of PD-1 + and LAG-3 + T reg cells, markers associated with suppressive effector T reg cells in humans, compared with NHCs 22,23 (Fig.”
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape
Inocencio, J. F., Mitrasinovic, S., Asad, M., Parney, I. F., Zang, X., & Himes, B. T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424396 · Cited by 23
Mahalingam, J., Lin, Y., Chiang, J., Su, P., Fang, J., Chu, Y., Huang, C., Chiu, C., & Lin, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0211 · Cited by 18
“TCM (CD45RA CCR7þCD4þ T cells) are noneffector memory T cells thatmainly circulate in the lymphoid organs.”
BackgroundInfluentialRen, Z., Yang, K., Zhu, L. D., Yin, D., & Zhou, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111934 · Cited by 17
Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
Talaat, I. M., Elemam, N. M., Zaher, S., & Saber-Ayad, M. M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.955599 · Cited by 17
“Additionally, LAG3 was reported to regulate the function of Treg cells, and its expression on CD4 CD25 cells was associated with potent inhibitory activity (71).”
BackgroundBeyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Li, Y., Kang, Z., & Du, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70018 · Cited by 22
Immunotherapy for head and neck cancer: Fundamentals and therapeutic development
Okano, S. (2024) · Auris Nasus Larynx · doi:10.1016/j.anl.2024.05.001 · Cited by 15
Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells
Pallikkuth, S., Pahwa, R., Kausalya, B., Saravanan, S., Pan, L., Vignesh, R., Iqbal, H. S., Solomon, S. S., Murugavel, K. G., Poongulali, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206256 · Cited by 14
Wu, Y., Yu, S., & Qiao, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.990445 · Cited by 16
“Tregs can either restrict the amount of effector T cells by depleting IL-2 (Setoguchi et al., 2005) or inhibit the function of effector T cells by producing TGF-β and IL-10 (Takahashi et al., 1998; Camisaschi et al., 2010).”
BackgroundInfluentialDeng, T., Liu, Z., Han, Z., Zhou, H., Liu, R., Li, Y., Li, S., Xiu, P., Wang, S., Zhang, Y., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231186025 · Cited by 14
Heterogeneity and subtypes of CD4+ regulatory T cells: implications for tumor therapy
Lin, H., Xu, Y., & Lin, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291796 · Cited by 15
The tumor microenvironment: Thousand obstacles for effector T cells
Massa, C., & Seliger, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.004 · Cited by 16
Sartorius, D., Blume, M. L., Fleischer, J. R., Ghadimi, M. B., Conradi, L., & Oliveira, T. D. (2023) · Cancers · doi:10.3390/cancers15215124 · Cited by 11
“In CRC patients LAG-3-positive Tregs produce IL-10 as wells as TGF-ß1 and are believed to be strongly activated and therefore directly involved in tumor immune evasion, due to direct contact inhibition of other T cells [203].”
BackgroundSears, T. J., Pagadala, M. S., Castro, A., Lee, K.-H., Kong, J., Tanaka, K., Lippman, S. M., Zanetti, M., & Carter, H. K. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0164 · Cited by 13
“In contrast, LAG3 has MHC-II as its major ligand (100), and it is widely regarded as a negative regulator of CD4 + T-cell activation (105).”
LAG ‐3—An incompletely understood target in cancer therapy
Leitner, J. M., Radakovics, K., & Steinberger, P. (2024) · The FASEB Journal · doi:10.1096/fj.202401639r · Cited by 12
The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia
Cocks, M. M., & Mills, A. M. (2021) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000782 · Cited by 14
Development of a LAG-3 immunohistochemistry assay for melanoma
Johnson, L., McCune, B. K., Locke, D., Hedvat, C. V., Wojcik, J. B., Schroyer, C., Yan, J. S., Johnson, K., Sanders-Cliette, A., Samala, S., et al. (2022) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2022-208254 · Cited by 14
“Lymphocyte-activation gene 3 (LAG-3, CD223) is a cell-surface molecule expressed on activated CD4+ and CD8+ T cells, as well as other immune cells (ICs) including regulatory T cells, natural killer cells, B cells, macrophages, and dendritic cells, and is under investigation as an I-O therapy target.[13-17] The interac…”
Identification of novel splice variants in horn cancer by RNA-Seq analysis in Zebu cattle
Patel, A. K., Bhatt, V. D., Tripathi, A. K., Sajnani, M. R., Jakhesara, S. J., KORINGA, P. G., & Joshi, C. G. (2012) · Genomics · doi:10.1016/j.ygeno.2012.10.001 · Cited by 14
Blinova, V. G., Novachly, N. S., Gippius, S. N., Hilal, A., Gladilina, Y. A., Eliseeva, D. D., & Zhdanov, D. D. (2021) · Applied Sciences · doi:10.3390/app11135776 · Cited by 12
“The CD4-related protein LAG-3 (CD223) has been implicated in suppressive functions of Tregs via direct interactions with Tregs and effector cells and via the modulation of antigenpresenting cells [16,17].”
BackgroundT cell unresponsiveness in a pediatric cystic fibrosis patient: a case report
Kushwah, R., Gagnon, S., & Sweezey, N. (2014) · Allergy Asthma and Clinical Immunology · doi:10.1186/1710-1492-10-2 · Cited by 12
“Although LAG-3 and CTLA-4 are not expressed on naïve T cells from healthy individuals [22,23], freshly isolated naïve CD4+ T cells from peripheral blood of our present patient showed sustained expression of LAG-3 and CTLA-4, which were further induced even upon ex vivo stimulation with cytokines that drive T cell prol…”
BackgroundAroldi, F., Saleh, R., Jafferji, I., Barreto, C. M. N., Saberian, C., & Middleton, M. R. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_6 · Cited by 12
Singh, R. K., Srivastava, P., & Manna, P. P. (2024) · Medical Oncology · doi:10.1007/s12032-023-02289-y · Cited by 12
“OX40 [125], GITR [126], and LAG-3 [127], which are mainly expressed by T-regulatory cells, are also possible choices for the depletion and functional modification of Treg cells.”
Farhangnia, P., & Akbarpour, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00165-8 · Cited by 18
Hossain, S. M., Lynch‐Sutherland, C. F., Chatterjee, A., Macaulay, E. C., & Eccles, M. R. (2021) · Epigenomes · doi:10.3390/epigenomes5030016 · Cited by 13
“Tregs uppress Teff cel s, promoting tumour malignancy and therapeutic resistance [22], such as in melanoma [21,23–27]. urther, secreted TGF-β plays a role in epithelial–mesenchymal transition (EMT) [28] and contributes to cancer invasion and dissemination.”
BackgroundInfluentialLAG3 immune inhibitors: a novel strategy for melanoma treatment
Wu, R., Zeng, M., Zhang, Y., & He, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1514578 · Cited by 12
Negative Immune Checkpoint Inhibitors
Drewniak‐Świtalska, M., Fortuna, P., & Krzystek‐Korpacka, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060713 · Cited by 12
Lactic acid improves Treg manufacturing and in vivo function
Tuomela, K., Leong, E. S. Y., Haque, M., Mangat, S., Fung, V. C. W., García, R., Archambault, A., Boardman, D. A., Geltink, R. I. K., Mojibian, M., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101600 · Cited by 13
“42 Likewise, TIM-3 expression on Tregs is associated with an effector-like and highly suppressive phenotype.”
Martin, C. M., & Enrico, D. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962947 · Cited by 11
Li, Y., Wang, W., Tian, J., Zhou, Y., Shen, Y., Wang, M., Tang, L., Liu, C., Zhang, X., Shen, F., et al. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231202650 · Cited by 11
Vallacchi, V., Camisaschi, C., Dugo, M., Vergani, E., Deho, P., Gualeni, A. V., Huber, V., Gloghini, A., Maurichi, A., Santinami, M., et al. (2016) · Genes · doi:10.3390/genes7120124 · Cited by 12
“Naïve CD4+CD25− T cells and expanded Tregs were cultured as previously described [14].”
MethodResultVazquez‐Mateo, C., Collins, J., Fleury, M., & Dooms, H. (2017) · BMC Immunology · doi:10.1186/s12865-017-0201-4 · Cited by 11
“Tregs expressing PD-1 [39], Tim-3 [31] and LAG-3 [30] are found at sites of active immune responses, e.”
Zhang, J., Liu, W., Xie, T., Huang, L., Hu, Y., Wen, B., Tang, P., Guo, F., Jin, K. L., Zhang, P., et al. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.06.003 · Cited by 11
Uemura, I., Takahashi‐Suzuki, N., & Satoh, T. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107024 · Cited by 9
Day, D., Ganju, V., Chung, K. Y., Si, L., Mao, L., Aghmesheh, M., Hoyer, R. J., Brewin, K., Zeng, S., Zhang, M., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02990-x · Cited by 14
“Additionally, LAG-3 is expressed by regulatory T cells in the tumor microenvironment, contributing to their suppressive activities [9].”
Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy
Kolb, H. R., Borcherding, N. C., & Zhang, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_12 · Cited by 12
Choi, Y., Lee, S.-E., Kim, D., Lim, H.-I., Choi, D. K., Park, B. K., Jeon, C., & Ko, S. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04064-6 · Cited by 8
Prognostic Impact of Tumor Immune Microenvironment and Its Predictive Role in Salivary Gland Cancer
Veneroni, M. V., Festa, B. M., Costantino, A., Spriano, G., Mercante, G., VIRGILIO, A. D., & Tommaso, L. D. (2023) · Head and Neck Pathology · doi:10.1007/s12105-023-01528-y · Cited by 8
“LAG3 demonstrated to be also associated with CD4+ CD25+Foxp3+ Treg cells defining a terminal-effector phenotype in cancer patient [68].”
BackgroundWaryah, C. B., Alves, E., Mazzieri, R., Dolcetti, R., Thompson, E. W., Redfern, A. D., & Blancafort, P. (2023) · Cancers · doi:10.3390/cancers15123152 · Cited by 9
“The origin of these inflammatory mediators varies within the tumor and may arise from various cell types, including polarized “M2-like” (Arg1high/CD206high/IL-10high) pro-tumoral macrophages (tumor-associated macrophages; TAMs) [128], myeloid-derived suppressor cells (MDSCs) [129], CD4+Foxp3+ regulatory T cells (Tregs…”
BackgroundNinkovic, S., Purton, L. E., Harrison, S. J., & Quach, H. (2023) · Haematologica · doi:10.3324/haematol.2023.283344 · Cited by 16
“In 32-34 Comprehensive molecular and phenotypic profiling of peripheral blood T cells isolated from patients with myeloma following an autoSCT not only demonstrates persistent checkpoint expression, but recognizes Lag-3 and PD-1 as potential immune biomarkers for identifying patients at higher risk…”
Al-Mterin, M. A., Murshed, K., & Elkord, E. (2022) · Vaccines · doi:10.3390/vaccines10091471 · Cited by 8
“Tregs expressing LAG-3 are highly suppressive and proliferative in CRC patients [7,31].”
BackgroundChe, X., Shen, Z., Sun, Y., Wang, X., Zhang, P., Cao, J., & Bai, Y. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.036 · Cited by 6
Lu, H., Teng, Z., Wang, J., & Zhang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583363 · Cited by 10
Pang, X., Li, X., Zhu, W.-H., Huang, R.-K., Mo, Z., Huang, Z.-X., Zhang, Y., Xie, D., & Gao, Z. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105592 · Cited by 6
Glycogen Synthase Kinase-3 (GSK-3) Regulation of Inhibitory Coreceptor Expression in T-cell Immunity
Issa, M. E., & Rudd, C. E. (2021) · Journal of Cellular Immunology · doi:10.33696/immunology.3.115 · Cited by 8
“Further, LAG-3+ Tregs exhibit superior suppressive activity when compared to LAG-3− Tregs, release more immunosuppressive cytokines IL-10 and TGFβl [47].”
BackgroundRoma, S., Camisaschi, C., Mancuso, P., Trabanelli, S., Vanazzi, A., Villa, S., Prati, D., Fiori, S., Lorenzini, D., Tabanelli, V., et al. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104615 · Cited by 6
Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors
Chew, H. Y., Dolcetti, R., & Simpson, F. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14338 · Cited by 6
“transforming growth factor beta-1 (TGF-β1) [138].”
Al-Mterin, M. A., Murshed, K., & Elkord, E. (2022) · Vaccines · doi:10.3390/vaccines10040538 · Cited by 6
“Moreover, LAG-3+ Tregs from colorectal cancer patients are highly suppressive and proliferative [32].”
BackgroundGao, Z., Zhang, Q., Zhang, X., & Song, Y. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221092900 · Cited by 7
Qi, W., Xi, D., Bai, Y., Liu, L., Ma, Y., Yin, Z., & Chen, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1026135 · Cited by 7
“LAG-3 binds to its ligand to form an immune checkpoint pathway independent of PD-1/PD-L1, leading to T cell dysfunction and tumor cell evasion of immune surveillance (Camisaschi et al., 2010).”
BackgroundKochin, V., & Nishikawa, H. (2019) · PubMed Central · doi:10.18999/nagjms.81.1.1 · Cited by 8
An, Z., Hsu, M. A., Gicobi, J. K., Xu, T., Harrington, S. M., Zhang, H., Pavelko, K. D., Hirdler, J. B., Lohse, C. M., Nabavizadeh, R., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200933 · Cited by 7
Non-coding RNA in tumor-infiltrating regulatory T cells formation and associated immunotherapy
Ma, Y., Xu, X., Wang, H., Liu, Y., & Piao, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1228331 · Cited by 10
Xiao, Y., Zheng, P., Xu, W., Wu, Z., Zhang, X., Wang, R., Huang, T., & Ming, J. (2024) · Translational research · doi:10.1016/j.trsl.2024.05.001 · Cited by 6
Tulsian, K., Thakker, D., & Vyas, V. K. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141364 · Cited by 6
LAG3 regulates antibody responses in a murine model of kidney transplantation
Nicosia, M., Fan, R., Lee, J., All, G. L., Gorbacheva, V., Valenzuela, J. I., Yamamoto, Y., Beavers, A., Dvorina, N., Baldwin, W. M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci172988 · Cited by 6
Advances in cancer immunotherapy: The role of super NK and super CAR-T cells
Almohaimeed, H. M., Chowdhury, A., Sarkar, S., Almars, A. I., Tounsi, W. A., Singh, A., Krithiga, T., Ray, S., & Uti, D. E. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115074 · Cited by 7
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation
Swatler, J., Luca, M. D., Rotella, I., Lise, V., Mazza, E. M. C., & Lugli, E. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0517 · Cited by 6
Interaction Between the Immune System and Melanoma
Norma, E. (2013) · InTech eBooks · doi:10.5772/54939 · Cited by 5
“Tregs constitutively express CD25 (IL-2 receptor α chain) on their cell surface and suppresses CD4+ and CD8+ effector T cells through the release of immunosuppressive molecules, consumption of IL-2 and direct cell to cell contact [40].”
BackgroundZhang, Y., Zhang, L., Sun, H., Liu, Y., Xu, J., Huang, H., Fu, J., Zhang, D., Tian, T., Zhao, Y., et al. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00373-5 · Cited by 5
Witte, H. M., Gebauer, N., & Steinestel, K. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103592 · Cited by 6
Wenzhong, Y., Jia, X., Yang, S., & Li, Q. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0008-3 · Cited by 5
LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathiesPreprint
Emmenegger, M., Cecco, E. D., Hruška-Plocháň, M., Eninger, T., Schneider, M. M., Barth, M., Tantardini, E., Rossi, P. D., Bacioglu, M., Langston, R. G., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.25.441302 · Cited by 5
Ghasemi, K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156163 · Cited by 4
Lan, X., Yang, T. T. C., Wang, Y., Qu, B., Rong, S., & Song, N. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13648 · Cited by 4
Immune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
Protein transport inhibitors downregulate the expression of LAG-3 on regulatory T cells
Anvari, S., Grimbergen, A., Davis, C. M., & Makedonas, G. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.04.006 · Cited by 9
Liefaard, L., Hajduk, E., van den Berg, F., Panoilia, E., Bouma, G., Lisi, E., Srinivasan, N., Cui, Y., Gross, A. S., Tarzi, R. M., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1165 · Cited by 4
Camisaschi, C., Tazzari, M., Rivoltini, L., & Castelli, C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0345-0_18 · Cited by 6
Shokrgozar, N., Karimi, M., Golmoghaddam, H., Rezaei, N., Moayed, V., Sharifzadeh, S., & Arandi, N. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04605-w · Cited by 5
Microenvironment, Crosstalk, and Immune Escape Mechanisms
Visser, L., van den Berg, A., Poppema, S., & Diepstra, A. (2014) · Hematologic malignancies · doi:10.1007/978-3-319-12505-3_4 · Cited by 3
Type 1 Regulatory T Cells and Their Application in Cell Therapy
Gu, C., & Oh, S. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.106852 · Cited by 4
Das Tumormikromilieu bei Speicheldrüsenkarzinomen – mögliche Konsequenzen für neue Therapiekonzepte
Meyer, M. F., Arolt, C., Kansy, B., Doescher, J., Quaas, A., Beutner, D., Lang, S., & Klußmann, J. P. (2020) · HNO · doi:10.1007/s00106-020-00926-w · Cited by 3
Regulatory T Cells in Tumor Immunity
Nagarsheth, N., Kryczek, I., Wei, S., Frankel, T. L., & Zou, W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17009-2 · Cited by 3
Pan, B., Li, S., Ye, R., Zhu, J., Tang, Y., & Li, L. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s561672 · Cited by 2
Zarrinrad, G., Burkhardt, L.-M., Beltran-Mestres, C., Romero‐Suárez, S., Wagner, D. L., Schlickeiser, S., Stein, M., Wendering, D. J., de la Cebosa, I. J. C. D., Ehlen, L., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201735 · Cited by 2
Liu, Z., Zhang, Y., & Wu, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115664 · Cited by 2
Gama, J. M., Teixeira, P., & Oliveira, R. C. (2024) · Onco · doi:10.3390/onco4030010 · Cited by 3
“Tregs are also associated with FoxP3 expression [46], so LAG-3 therapy may be an excellent therapeutic tool in patients whose tumors present higher expression of these cells in their TME.”
BackgroundLi, S., Pan, Y., Ye, R., Wang, Y., & Li, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113717 · Cited by 2
Regulatory T cells in the tumor microenvironment display a unique chromatin accessibility profile
Dadey, R., Cui, J., Rajasundaram, D., Yano, H., Liu, C., Cohen, J. A., Liu, A. W., Kaplan, D. H., Workman, C. J., & Vignali, D. A. A. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlae014 · Cited by 2
“64 68 Moreover, Lag3 þ T regs have been shown to produce high amounts of TGFB3 in murine models of humoral immune response and lupus.”
Guth, A., & DOW, S. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2362-5.00013-x · Cited by 5
Role of Regulatory T cells in Epilepsy
Xu, D., Koh, S., & Miller, S. D. (2021) · Progress in inflammation research · doi:10.1007/978-3-030-67403-8_9 · Cited by 3
Current Trends in Immuno-Oncology
Vanteddu, V. G., Bawari, S., & Patel, T. D. (2022) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525720666220829142225 · Cited by 5
Zhu, J., & Chen, J. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08220-4 · Cited by 2
“In the tumor environment, LAG-3-positive Treg cells spontaneously aggregate to the tumor site and suppress the activity of killer T cells [39].”
BackgroundOvercoming Cancer Tolerance with Immune Checkpoint Blockade
Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2
Microenvironment, Cross-Talk, and Immune Escape Mechanisms
Visser, L., Veldman, J., Poppema, S., van den Berg, A., & Diepstra, A. (2020) · Hematologic malignancies · doi:10.1007/978-3-030-32482-7_4 · Cited by 2
Kim, D., Kim, G., Yu, R., Lee, J., Kim, S., Qiu, K., Montauti, E. I., Fang, D., Chandel, N. S., Choi, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.13.528371 · Cited by 2
Qi, C., Zhao, Z., Qi, Y., Zhou, Y., Yue, F., Niu, H., Duan, G., Zhong, Z., & Wang, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1502380 · Cited by 1
Varmazyari, S., Borhani, H., Moradipour, Z., Ziaei, H., & Rezaei, N. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-03176-1_18 · Cited by 2
Tripathi, S., Julé, A. M., Zhu, Z., Schreiber, B., Martín-Moreno, P. L., Sui, S. H., Waaga-Gasser, A. M., & Chandraker, A. K. (2026) · Scientific Reports · doi:10.1038/s41598-025-33656-6 · Cited by 1
Integrative analysis identified the key role of LAG3 in T cell exhaustion in glioma
Wang, Z., Fu, H., Li, Y., Liu, Z., Fan, W., Liu, Y., ZHANG, C., Liang, J., Zhang, Z., Zhong, L., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-04416-3 · Cited by 1
“Lymphocyte-activation gene 3 (LAG3) is an immune checkpoint predominantly expressed on the surface of various immune cells, including T cells, natural killer cells, and certain myeloid cells [1].”
Plasmacytoid Dendritic Cells Are Key Regulators of Immune Tolerance
Matta, B. M. (2012) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
The CD4-like molecule LAG-3, biology and therapeutic
Sierro, S. R., Romero, P. J., & Speiser, D. E. (2011) · Cited by 1
Park, H. J., Oh, J. H., & Ha, S. (2016) · Journal of Visualized Experiments · doi:10.3791/54138 · Cited by 1
ROLE OF THE REGULATORY T CELLS IN PROGRESSION OF PROSTATE CANCER
Popov, S. V., Стуров, Н. В., Vorobyev, N. V., & Khaidukov, S. V. (2019) · Medical Immunology (Russia) · doi:10.15789/1563-0625-2019-4-587-594 · Cited by 1
LAG-3 Inhibitors for the Treatment of Lung Cancer
Sankpal, K., Morparia, S., Suvarna, V., & Murahari, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_8 · Cited by 2
Saha, P., Hasib, M. A., Halder, B., Sultana, S., & Rafe, M. R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106589 · Cited by 2
Lymphocyte Activation Gene 3 (LAG-3)
Sunshine, J. C., & Lipson, E. J. (2017) · Springer eBooks · doi:10.1007/978-1-4419-0717-2_136 · Cited by 1
Metadata
- Authors
- Camisaschi, C., Casati, C., Rini, F., Perego, M., De Filippo, A., Triebel, F., Parmiani, G., Belli, F., Rivoltini, L., & Castelli, C.
- Affiliations
- Unit of Immunotherapy of Human Tumors
- Immutep S.A., Faculté de Pharmacie , Chatenay-Malabry,
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Corresponding author
- Camisaschi, Chiara
- Casati, Chiara
- Rini, Francesca
- Perego, Michela
- Parmiani, Giorgio
- Rivoltini, Licia
- Castelli, Chiara
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06-01
- Volume
- 184
- Issue
- 11
- Pages
- 6545-6551
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147968481
- Cited by
- 350
- References
- 49
- Citations by year
- 2026: 9 · 2025: 23 · 2024: 30 · 2023: 21 · 2022: 46 · 2021: 36 · 2020: 35 · 2019: 29 · 2018: 22 · 2017: 16 · 2016: 17 · 2015: 10 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- LAG-3, regulatory T cells, Foxp3, CD4+CD25high T cells, tumor-infiltrating lymphocytes, metastasis, immunosuppression, IL-10, TGF-β1, suppressor activity, cell-cell contact, tumor immunology, T cell subsets
- MeSH terms
- Lymphocyte Activation Gene 3 Protein, Cell Separation, Flow Cytometry, Humans, Lymphocyte Activation, Neoplasms, Antigens, CD, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.